Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study.

Mary E Westerman Kelly K Bree Pavlos Msaouel Janet Baack KukrejaCheryl MantaringInnocent RukundoMartha Garcia Gonzalez Justin R Gregg Kelly N Casteel Surena F Matin

Published in: The Journal of urology (2022)

There were fewer compliance events using apixaban for EP than enoxaparin after urologic oncology surgery. Regarding safety, apixaban is noninferior to enoxaparin and may in fact have fewer associated major complications.

Keyphrases

venous thromboembolism
quality improvement
atrial fibrillation
minimally invasive
palliative care
risk factors
coronary artery disease
acute coronary syndrome
percutaneous coronary intervention